Recently funded awards

This page lists the investigator-led programmes, projects and fellowships that we supported through our response-mode grant funding schemes committee meetings during 2018.

Details of decisions made in 2018 by our Drug Discovery Committee, New Agents Committee and Pioneer Awards Committee will be published later in the year.

Select a funding committee to see what they funded last year:

Advanced Clinician Scientist Fellowships

Sean Lim, University of Southampton
Exploiting the innate and adaptive immune interface for effective cancer therapy

Simon Buczacki, University of Cambridge
Contextual clonogenicity in differentiated colorectal cancer cells: understanding the ‘reserve’ cancer stem cell

David Church, University of Oxford
Mechanisms and consequences of hyper/ultramutation in colorectal and endometrial cancer

Paolo Gallipoli, University of Cambridge
Identification and characterisation of metabolic pathways as determinants of drug resistance in acute myeloid leukaemia

 

Clinician Scientist Fellowships

Thomas Mitchell, Wellcome Trust Sanger Institute
Understanding the multi-cellular microenvironment of renal cell carcinoma

David O’Connor, University College London
Identifying the genetic and functional drivers of chemoresistant T-cell acute lymphoblastic leukaemia

Amit Roshan, University of Cambridge
Molecular risk stratification of early stage melanoma by identifying early genetic events and ultra-sensitive detection of circulating tumour DNA

Simon Richardson, University of Cambridge
Characterisation of altered epigenetic cell states following loss of CREBBP function and their role in the induction and treatment of ALL

 

Pre-doctoral Research Bursaries

Mareike Thompson, University of Cambridge
Analysis of circulating tumour DNA (ctDNA) in patients with glioblastoma leveraging samples collected in the PARADIGM trial

Rachael Pocock, UCL Cancer Institute
Examining the role of Reptin and its interaction with the transcription factor MYB as a driver of leukaemogenesis in T-ALL

Edward Poynton, Queen Mary, University of London
Investigating circulating tumour DNA as a multi-purpose surveillance tool in follicular lymphoma

Akshay Patel, University of Birmingham
Is B cell Immune phenotype predictive of outcome and toxicity with combination checkpoint blockade in Non-small cell lung cancer patients?

Samuel Withey, King's College London 
Utilising a radiogenomics approach for predicting therapy response in patients with primary oesophageal cancer undergoing neoadjuvant therapy

 

CRUK/Pathological Society Pre-doctoral Research Bursaries

Lorelle Brownlee, University College London
Tumour evolution in neuroendocrine lung cancers

Sophie Prendergast, University College London
Genomic profiling of adamantinoma

Hannah Crane, University of Sheffield
Exploring chemotherapy resistance in HPV-positive and HPVnegative Oropharyngeal Squamous Cell Carcinoma (OPSCC)

Dr Vinaya Srirangam Nadhamuni, Queen Mary, University of London 
Growth hormone-secreting pituitary adenomas: The link between AIP mutations and resistance to treatment with somatostatin analogues

 

Postdoctoral Research Bursaries

Kezia Gaitskell, University of Oxford
The molecular pathological epidemiology of ovarian cancer in the million women study: a pilot study

Kate Marks, University of Leeds
Understanding the rate limiting events that determine the fixation and spread of somatic mutations in normal and diseased bowel mucosa and how they lead to colorectal cancer

Elaine Leung, University of Glasgow 
Deciphering the role of the CCR7/CCL21 chemokine axis in ovarian cancer

Saif Ahmad, University of Cambridge
Deciphering the role of androgen receptor mediated upregulation of DNA repair capacity as a driver of breast cancer radioresistance

Sally George, Institute of Cancer Research
Therapeutic targeting of the DNA damage response pathway in neuroblastoma with alterations in ATRX and alternative lengthening of telomeres (ALT)

Rasheed Zakaria, University of Liverpool 
BRain dIffusion TEnsor imaging to predict immunotherapy response in METastatic melanoma (BRITEMET)

John Findlay, University of Oxford 
Augmenting clinical decision-making and predicting success of first-line therapies for oesophageal cancer using multi-omics and artificial intelligence

Biomarker Project Awards

Dr Sudha Sundar and Dr James Brenton, University of Birmingham
ROCKETS-GEN: Earlier detection of ovarian cancer using novel genomic technology

 

Clinical Trial Awards*

Professor Mererid Evans, Professor Terence Jones and Professor Christian Simon, Cardiff University
PATHOS: Post-operative adjuvant treatment for HPV-positive tumours

Professor Maria Hawkins, University College London
ABC-07: Addition of stereotactic body radiotherapy to systemic chemotherapy in locally advanced biliary tract cancers

Dr Geoff Higgins, University of Cambridge
ARCADIAN: Phase I study combining the tumour hypoxia modifier atovaquone with radical chemoradiotherapy in locally advanced NSCLC

Dr Anthony Kong, University of Birmingham
TWEET: A randomised phase II Trial of WEE1 inhibitor (AZD1775) with Taxane chemotherapy (paclitaxel) versus paclitaxel in head and neck squamous cell carcinoma

Dr Adam Mead, University of Birmingham
PROMise: Investigation into the combination of a Plexxikon BETi with ruxolitinib in patients with high or intermediate-2 risk myelofibrosis not receiving an adequate response with ruxolitinib alone

Dr John Moppett, University College London
ALLTogether-1: A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)

Professor Carlo Palmieri and Dr Anthony Kong, University of Birmingham
RADIANT-BC: A multi-cohort Phase Ib/expansion cohort study of the efficacy and safety of radiosurgery with durvalumab followed by durvalumab and standard of care systemic therapy in patients with brain metastases secondary to breast cancer

Endorsements

Professor Gareth Griffiths and Professor Dean Fennell, University of Southampton
IND227: A phase II/III randomised trial of pembrolizumab in patients with advanced malignant pleural mesothelioma

Professor Gareth Griffiths, Professor Robert Huddart and Dr Simon Crabb, University of Southampton
BL13: A randomised phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer

Dr David Chang, University of Glasgow
PRIMUS-004: Second line Chemotherapy for metastatic pancreatic cancer

Dr Susana Banerjee and Professor Judith Bliss, Institute of Cancer Research
ATARI: ATr inhibitor in combination with olaparib in gynaecological cancers with ARId1A loss or no loss

Extension

Professor Robert Hills and Professor Nigel Russell, Cardiff University
AML18: A trial for older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome

Renewal

Professor Gary Middleton, University of Birmingham
LungMatrix: Multi-drug, genetic marker-directed, non-comparative, multi-centre, multi-arm phase II trial in non-small cell lung cancer

 

Prospective Sample Collection Awards

Dr Marcia Hall, University of Glasgow
TRANS CeNtuRIOn

 

Clinical Trial Fellowships

Dr John Apps, Leeds Clinical Trials Research Unit

Dr Alexandra Gilbert, Cancer Research UK Clinical Trial Unit Birmingham

Dr Magdalena Meissner, Wales Cancer Trials Unit

 

*This list includes grants awarded under our Early Phase and Feasibility Study Awards and Late Phase Clinical Trial Awards, which were replaced in 2018 with the single Clinical Trial Awards scheme

Early Detection Programme Awards

Kwee Yong, University College London, Irene Ghobrial, Broad Institute Harvard University, and Karthik Ramasamy, University of Oxford
Defining risk in smouldering myeloma (SMM) for early detection of multiple myeloma (MM)

Early Detection Project Awards

Matthew Baker and Paul Brennan, University of Strathclyde
Validating serum diagnostics for early diagnosis and stratification of glioma

Kevin Ryan, Cancer Research UK Beatson Institute 
Identification of biomarkers for the detection of pre-cancerous lesions associated with pancreatic ductal adenocarcinoma 

Adam Brentnall and Giovanni Montana, Queen Mary University of London          
An artificial intelligence system for real-time risk assessment at mammography screening

Sam Janes, University College London           
ASCENT: analysis of screen-detected lung cancers genomic traitsERBB

John Doorbar, University of Cambridge
A novel patch sampling approach for grading and generating cervical disease maps

Early Detection Primer Awards

Karen Pooley, University of Cambridge               
Evaluation of microRNAs as biomarkers in the early detection of breast cancer blood

Rachel Evans, University College London          
Early detection of lung cancer using a molecular tracer

Elizabeth Soilleux, University of Cambridge               
Developing a novel high sensitivity (capture-based) clonality test for the early detection of lymphoid neoplasia, including lymphoma, myeloma and lymphoid leukaemia

Paul Barber, University College London
Exosomal protein dimers as an early detection biomarker for lung cancer

Rosamonde Banks, University of Leeds         
Exploring the use of tumour-associated autoantibodies in the early detection of renal cancer 

Helen Coleman and Kathleen Curtius, Queen's University Belfast and Queen Mary University of London
Understanding the molecular age of Barrett’s oesophagus in a population-representative sample of patients spanning paediatric to older age groups

Daniel Richards and Marta Broto Aviles, Imperial College London              
Developing ultra-sensitive lateral flow immunoassays for the early detection of ovarian cancer

Joseph Jacob, University College London           
Applying an attention based time aware recurrent neural network model to predict pulmonary nodule evolution in lung cancer screening patients

Sara Zanivan, Cancer Research UK Beatson Institute 
Exploring deep plasma redox-proteome profiling for early detection of HCC  

Early Detection Innovation Awards 

Sensor technology for liquid biopsy sandpit

Team EpiEnrich led by Charlie Massie at CRUK Cambridge Institute
Will enrich liquid biopsy samples by concentrating nucleosomes and then removing the bits of DNA that are bound to them.

Team ExoPop led by Dave Carter at Oxford Brookes University
Will identify the contents (defining signatures) of extracellular vesicles in liquid biopsies by popping them on a probe using current.

Team Quantum Leapers led by Melissa Mather at University of Nottingham
Will explore a new platform for analysing metabolomic profiles in liquid biopsies that uses a diamond sensor, which can create spectra like NMR.

Team TEP-eDx led by Beth Psaila at University of Oxford
Will identify characteristics and develop sorting techniques to capture tumour educated platelets from blood.

Career Development Fellowship

Dr Charles Massie, University of Cambridge
Early events in prostate cancer: causes, consequences and opportunities for precision medicine in early prostate cancers

Dr Alexis Barr, Imperial College London
Understanding proliferation-quiescence decisions in response to DNA damage

Dr Emma Kerr, Queen’s University Belfast
Defining metabolic mechanisms of drug resistance in colorectal cancer

Dr Kasper Rasmussen, University of Dundee
Aberrant DNA methylation and its impact in blood cancer development

Dr Raheleh Rahbari, The Wellcome Trust Sanger Institute
Pathogenic variants and clonal dynamics in normal and cancerous testes and their role in cancer predisposition

 

Career Establishment Award

Dr Helen Coleman, Queen’s University Belfast
Epidemiology and molecular pathology epidemiology of Barrett's oesophagus and oesophageal adenocarcinoma in the modern treatment era

Dr Alan Serrels, University of Edinburgh
Defining the mechanisms of FAK-dependent immune evasion in Pancreatic Cancer

Dr Kendle Maslowski, University of Birmingham
Mechanisms of attenuated Salmonella cancer therapy–metabolic reprogramming and immune modulation

 

Senior Cancer Research Fellowship

Dr Adam Mead, University of Oxford
Unravelling cancer stem cell heterogeneity in myeloproliferative neoplasms

Dr Ferdia Gallagher, University of Cambridge
Hyperpolarised carbon-13 MRI for metabolic imaging of renal cell carcinoma

Programme Grants

Gary Collins, University of Oxford
A Programme of Applied Statistical Methodology Research

Richard Gray, University of Oxford
Early breast cancer meta-analyses and trials: Early Breast Cancer Trialists' Collaborative Group (EBCTCG) and the AgeX NHS breast screening trial

Peter Sasieni, King’s College London
Cancer Screening & Statistics

 

Project Grants

Abigail Fisher, University College London
Advancing survival cancer outcomes trial (ASCOT); long-term follow-up

Jesper Lagergren, King’s College London
Circulating sex hormone levels and risk of oesophageal adenocarcinoma

Mark Rutherford, University of Leicester
Providing detailed insight into the impact of a cancer diagnosis across a full pathway for cancer patients: development and application of novel methodology

Michael Ussher, University of Stirling
A qualitative study of factors influencing adherence among pregnant women attempting to stop smoking with the aid of electronic cigarettes

 

Population Research Postdoctoral Fellowship

Tanimola Martins, University of Exeter
Ethnic inequality in diagnosis and outcomes in cancer

Hannah Littlecott, Cardiff University
Using social network analysis to understand the role of school-based social diffusion processes in smoking initiation among adolescents in contemporary Western society

Leah Jayes, University of Nottingham
Preventing relapse to smoking among prisoners after release

 

Catalyst Award

TBA spring 2019

Programme Awards

Christian Siebold, University of Oxford
Molecular Mechanisms of Morphogen Signalling at the Cell Surface

Kamil Kranc, Queen Mary, University of London
Targeting RNA metabolism to expand haematopoietic stem cells and eredicate acute myeloid leukaemia

Jeffery Pollard, University of Edinburgh
Systemic and local influences of cancer on myeloid cell biology promote tumor malignancy

Shonit Punwani, University College London
Novel microstructural (VERDICT and T2 mapping) and metabolic (hyperpolarised 13C-Pyruvate) MR in diagnosis, risk-stratification and treatment response assessment of prostate cancer

Juan Pedro Martinez-Barbera, Institute of Child Health and University College London
Characterisation of the pro-tumourigenic activities of cellular senescence in adamantinomatous craniopharyngioma and preclinical validation of novel therapies

Stephen Royle, University of Warwick
Mitotic spindle stability and chromosome missegregation in cancer

Simon Robinson, The Institute of Cancer Research
Advancing MRI Biomarkers of the Tumour Microenvironment for Patient Benefit

Renewals

Bart Vanhaesebroeck, University College London
PI3Kalpha and PI3Kdelta in cancer biology and therapy

Kim Nasmyth, University of Oxford
How does cohesin regulate transcription in mammalian cells and how does this go awry in tumour cells?

Frances Balkwill, Queen Mary University of London
Targeting the innate immune system in high grade serous ovarian cancer

Jessica Downs, The Institute of Cancer Research
Investigating the contribution of chromatin dynamics to DNA damage responses and genome stability

Keith Caldecott, University of Sussex
A Novel Role for PARP Activity During Normal S phase and its Impact on Genome Stability and Cancer

Ian Tomlinson, University of Birmingham
Using predisposition genes to understand and prevent colorectal cancer

Philip Jones, Wellcome Trust Sanger Institute
Reshaping the mutational landscape in oesophageal squamous pre-cancer

Henning Walczak, University College London
Understanding the tumour-supportive functions of endogenous TRAIL and LUBAC in the context of cancer immunotherapy

 

Programme Foundation Awards

Cristina Lo Celso, Imperial College London
Understanding the competition between healthy and malignant haematopoiesis within the bone marrow microenvironment: from mechanisms to targets

Simon Mendez-Ferrer, University of Cambridge
Microenvironmental metabolic regulation in myeloid malignancies

Christian Frezza, University of Cambridge
The role of Fumarate Hydratase loss and fumarate accumulation in the predisposition to renal cancer

 

Multidisciplinary Project Awards

Mieke Van Hemelrijck and Anthony Coolen, King’s College London
New quantitative tools for precision medicine: overfitting correction in multivariate Cox analysis

Paul Beard and Brian Davidson, University College London
Photoacoustic-guided minimally invasive treatment of liver cancer

David Klenerman and Kevin Brindle, University of Cambridge
New biophysical tools to elucidate the role of P53 aggregates in cancer biology

Andrew Povey, University of Manchester, Perdita Elizabeth Barran (Manchester), David Mark Williams, University of Sheffield, Nicholas H Williams (Sheffield), Geoffrey Paul Margison (Manchester)
Identification and nucleotide resolution mapping of alkyl adducts in human DNA

 

Cancer Immunology Project Awards

Mala Maini, University College London
Overcoming metabolic checkpoints for T cell immunotherapy of liver cancer

Lucy Walker, University College London
Identifying autoimmune signatures in patients receiving checkpoint immunotherapy

Michelle Bombardieri and Hemant Kocher, Queen Mary University of London
Anti-tumour specificity and functionality of monoclonal antibodies derived from single lesional B cells from ectopic germinal centres in pancreatic ductal adenocarcinoma

Cecilia Johansson, Imperial College London
Cancer and viral infections in the lung - a delicate balance of microenvironments

More facts and figures about our research funding

Facts and figures about our research funding

Find out more about how and where we supported research in the last year with our interactive map and infographics.

Funding committees

Successful applicant case studies

Find out how our current grantees successfully applied for funding.

Read more

Our Research Prizes

Do you know somebody whose exceptional research merits reward and recognition? Nominate the rising stars and inspiring leaders of cancer research for our Research Prizes by 31 March.

Find out more